--------------------------------------------------------------------------------
--------------------------------------------------------------------------------





                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549





                                    FORM 8-K


                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


                Date of Report (Date of earliest event reported):
                       October 26, 2001 (October 26, 2001)


                          BioMarin Pharmaceutical Inc.
             (Exact name of registrant as specified in its charter)




          Delaware                 000-26727                68-0397820
(State or other jurisdiction      (Commission            (IRS Employer
       of incorporation)          File Number)           Identification No.)


     371 Bel Marin Keys Boulevard,                          94949
              Suite 210                                   (Zip Code)
         Novato, California
(Address of principal executive offices)


                                 (415) 884-6700
              (Registrant's telephone number, including area code)












--------------------------------------------------------------------------------
--------------------------------------------------------------------------------







Item 5.       Other Events

On October 26, 2001, we announced  our  financial  results for the quarter ended
September  30, 2001 in a press  release,  dated  October 26, 2001. A copy of the
press  release is attached  hereto as Exhibit  99.1 and  incorporated  herein by
reference.


Item 7.       Financial Statements and Exhibits

EXHIBIT NO.   DESCRIPTION OF DOCUMENT
--------------------------------------------------------------------------------
99.1          Press  Release  Dated  October 26,  2001  related to  announcement
              of third quarter 2001 financial results.


                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                BioMarin Pharmaceutical Inc.

                                By: /s/ Raymond W. Anderson
                                    --------------------------------------------
                                    Raymond W. Anderson
                                    Chief Operating Officer, Chief Financial
                                    Officer, Secretary and Vice President
                                    Finance and Administration



Date:  October 26, 2001

                                  Exhibit Index

EXHIBIT NO.   DESCRIPTION OF DOCUMENT
--------------------------------------------------------------------------------
99.1          Press  Release  Dated  October 26,  2001  related to  announcement
              of third quarter 2001 financial results.